supply chain
Drugmakers Push US Expansion After Trump’s 100% Pharma Tariff Threat
Trump tariff; pharmaceuticals; US manufacturing; branded drugs; drugmakers; Genentech; Roche; Novo Nordisk; Section 232; supply chain
Rethinking Strategies in Pharma Amidst Supply Chain Disruptions
pharma; supply chain; cost control; capability building
FDA Launches Pilot Program to Prioritize U.S. Generic Drug Manufacturing and Testing
FDA; pilot program; generic drugs; ANDA prioritization; domestic manufacturing; bioequivalence testing; U.S. pharmaceutical supply chain; drug approval; supply chain resilience
Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries
Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices
Celltrion Acquires Eli Lilly’s New Jersey Manufacturing Site for $330 Million
Celltrion; Eli Lilly; New Jersey site; acquisition; biopharmaceutical manufacturing; US tariffs; contract manufacturing; supply chain; biosimilars; investment
GSK Commits $30 Billion to Bolster U.S. R&D and Manufacturing
GSK; $30 billion investment; U.S. expansion; R&D; manufacturing; biopharma; supply chain; advanced digital technologies
Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)
cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth
Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times
pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO
Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership
Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward
Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin